1-Bromohexyl(triphenyl)phosphanium;bromide | 117753-71-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-Bromohexyl(triphenyl)phosphanium;bromide
• CAS: 117753-71-6
• 化学式: Br*C₂₄H₂₇BrP
• 分子量: 506.26
• InChiKey: YUYLORYMNRCMRJ-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  3.29
• 重原子数：
  27
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  hexylidenetriphenylphosphoran 在 1,1,2,2-四氟-1,2-二溴乙烷 作用下， 以 乙醚 为溶剂， 反应 0.5h， 以89%的产率得到1-Bromohexyl(triphenyl)phosphanium;bromide
  参考文献：
  名称：

  磷鎓叶立德与全卤代烷烃的新型反应：磷鎓叶立德的嗜盐攻击的第一个实例以及制备α-卤代烷基phosph盐的简便途径

  摘要：

  鏻叶立德博士3 PCHR（R = H，CH 3，C 2 H ^ 5，NC 3 ħ 7，NC 5 H ^ 11）容易反应与perhalofluoroalkanes，得到区域专一性α-haloalkylphosphonium盐博士3 P + -CHXRÿ - （X = I，Br，Cl），收率高。这些反应揭示了yl的一种新型反应性，即对CX键的嗜盐攻击，对于通过维蒂希反应进行取代卤代烯烃的区域特异性合成可能有用。

  DOI：

  10.1016/s0040-4039(01)91362-0

文献信息

• [EN] DEFEROXAMINE DERIVATIVES AS MEDICAMENTS<br/>[FR] DÉRIVÉS DE DÉFÉROXAMINE UTILISÉS EN TANT QUE MÉDICAMENTS
  申请人：BIOTECHNOLOGICKY USTAV AV CR V V I

  公开号：WO2019015701A1

  公开（公告）日：2019-01-24

  The present invention provides deferoxamine derivatives of general formula I and pharmaceutically acceptable salts thereof, (I) wherein at least one of R1 and R2 is a substituent of formula II. The novel derivatives are particularly suitable as medicaments, preferably for the treatment of cancer. Pharmaceutical preparations of compounds of formula I and a metal, preferably gallium, are also provided, resulting in even more active medicaments or contrast agents. Combinations with other agents, resulting in synergistic effects, are provided.

  本发明提供了通式I的去铁胺衍生物及其药用盐，其中R1和R2中至少有一个是通式II的取代基。这些新颖的衍生物特别适用作药物，优选用于癌症治疗。还提供了通式I化合物和金属，优选为镓的药用制剂，从而产生更活性的药物或对比剂。提供了与其他药剂的组合，产生协同效应。
• DEFEROXAMINE DERIVATIVES AS MEDICAMENTS
  申请人：Biotechnologicky Ustav AV CR, V.V.I.

  公开号：EP3655414A1

  公开（公告）日：2020-05-27
• [EN] TRIPHENYLPHOSPHONIUM BIGUANIDE ANALOGUES, THEIR METHOD OF PREPARATION AND USE AS DRUGS<br/>[FR] ANALOGUES DE BIGUANIDE DE TRIPHÉNYLPHOSPHONIUM, LEUR PROCÉDÉ DE PRÉPARATION ET LEUR UTILISATION COMME MÉDICAMENTS
  申请人：KKCG SE

  公开号：WO2016155679A1

  公开（公告）日：2016-10-06

  The present invention provides triphenylphosphonium biguanide analogs of general formula (I), whereas the general formula (I) includes resonance structures and pharmaceutically acceptable salts, protonated form as well as free base, (Formula (I)) where each one of R1, R2, R3, R4, R5, R6, R7 is independently selected from the group comprising H; C1-C6 alkyl; C6-C10 aryl; (C1-C6)alkyl(C6-C10)aryl; -C(=O)-R'; -C(=O)OR'; -C(=O)NR'R"; -C(=S)R'; -C(=S)NR'R''; wherein R' and R" are independently selected from the group comprising H, C1-C6 alkoxy, C1-C6 alkyl, C6-C10aryl, (Cl-C6)alkyl(C6-C10)aryl; whereas C1-C6 alkoxy, C1-C6 alkyl, C6-C10 aryl, (C1-C6)alkyl(C6-C10)aryl can be unsubstituted or substituted by one or more substituents selected independently from the group comprising C1-C4 alkyl, N(H or C1-C4 alkyl)2, wherein alkyls are the same or different, phenyl, benzyl, OH, SH, F, CI, Br, I, C1-C4alkoxy, C1-C4 acyloxy, C1-C4 mercapto; and substituent of general formula (II) (Formula (I)) wherein Z is as defined in the claims, whereas at least one of R1, R2, R3, R4, R5, R6, R7 is the substituent of general formula (II), X- is a pharmaceutically acceptable anion, preferably an anion of inorganic or organic acid, Y- is a pharmaceutically acceptable anion, preferably an anion of inorganic or organic acid. The invention further provides a method of preparation of these derivatives. These new compounds are suitable in particular for the treatment of diabetes mellitus type 2 and/or pancreatic carcinoma.